Effective Delivery of PEGylated siRNA to Tumors after Intraperitoneal Administration
Author Information
Author(s): Akul Singhania, Sherry Y. Wu, Nigel A. J. McMillan
Primary Institution: The University of Queensland Diamantina Institute, Princess Alexandra Hospital, The University of Queensland
Hypothesis
Can PEGylated liposomes effectively deliver siRNA to extraperitoneal tumors following intraperitoneal administration?
Conclusion
PEGylated liposomes can efficiently deliver siRNA to extraperitoneal tumors, resulting in a significant reduction in tumor size.
Supporting Evidence
- PEGylated liposomes showed a 10-fold decrease in macrophage uptake compared to non-PEGylated liposomes.
- PEGylated liposomes delivered 65.9% of the total dose to tumors, compared to only 7.5% for non-PEGylated liposomes.
- A 45% reduction in tumor size was observed with PEGylated siE6/7 lipoplexes compared to vehicle-only treatment.
Takeaway
This study shows that special liposomes can help deliver medicine to tumors outside the belly more effectively, which can help treat cancer.
Methodology
Mice were treated with either PEGylated or non-PEGylated lipoplexes containing siRNA, and tumor sizes were measured after treatment.
Potential Biases
Potential bias in the selection of treatment groups and the small sample size.
Limitations
The study primarily focused on one type of cancer and may not be generalizable to all cancer types.
Participant Demographics
2-month-old female C57B/6 mice were used in the study.
Statistical Information
P-Value
<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website